RT Journal Article
SR Electronic
T1 Testing for SARS-CoV-2 among cruise ship travelers repatriated to the United States, February–March 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.07.21258318
DO 10.1101/2021.06.07.21258318
A1 Waltenburg, Michelle A.
A1 Pomeroy, Mary A.
A1 Hughes, Laura
A1 Gold, Jeremy A.W.
A1 Mayer, Oren
A1 Vang, Arnold
A1 Hallowell, Benjamin D.
A1 Foster, Loretta
A1 Xu, Kerui
A1 Espinoza, Rita
A1 Hsieh, Kristina
A1 Pieracci, Emily G.
A1 Wuyke, Gabriella
A1 Da Silva, Juliana
A1 McClung, R. Paul
A1 Steinberg, Jonathan
A1 Westercamp, Matthew
A1 Vallabhaneni, Snigdha
A1 Li, Jessica
A1 Valderrama, Amy L.
A1 Grimes, George R.
A1 Harvey, R. Reid
A1 Nett, Randall J.
A1 Stokes, Kindra
A1 Lindstrom, Stephen
A1 Miller, Allison D.
A1 Griggs, Eric P.
A1 Milucky, Jennifer L.
A1 Bjork, Adam
A1 Albrecht, Valerie
A1 Kuhnert, Wendi L.
A1 Gould, Carolyn V.
A1 Knight, Nancy W.
A1 Nelson, Noele P.
A1 Honein, Margaret A.
A1 Behravesh, Casey Barton
A1 ,
A1 Dubray, Christine L.
A1 Marx, Grace E.
YR 2021
UL http://medrxiv.org/content/early/2021/06/09/2021.06.07.21258318.abstract
AB Background In early 2020, an outbreak of coronavirus disease 2019 occurred among passengers and crew of the Diamond Princess cruise ship. During February 16–17, some US citizens, residents, and their partners voluntarily repatriated to the US from Japan.Methods We conducted a retrospective, longitudinal evaluation of repatriated travelers where the outcome of interest was a positive test for SARS-CoV-2. Travelers who tested positive for SARS-CoV-2 were isolated in hospitals or at home under county isolation orders and underwent serial testing by real-time reverse transcription polymerase chain reaction (RT-PCR) approximately every other day, as contemporaneous US guidance required two consecutive negative tests collected ≥24 hours apart and symptom improvement before release from isolation.Results Among quarantined repatriated travelers, 14% tested positive for SARS-CoV-2. One-fifth of infected travelers initially tested negative but were identified on subsequent testing. All infected travelers remained asymptomatic or developed mild symptoms during isolation. Many travelers remained in prolonged isolation because of persistent viral detection based on contemporaneous policies.Conclusion Our findings support testing within 3-5 days after possible SARS-CoV-2 exposure to comprehensively identify infections and mitigate transmission and lend support to symptom- and time-based isolation recommendations, rather than test-based criteria.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no financial support for the research, authorship, and/or publication of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Case investigation, data collection, and analysis were conducted for public health purposes. This project was reviewed by the National Center for Emerging and Zoonotic Infectious Diseases Human Subjects Contact at the Centers for Disease Control and Prevention (CDC). The project was determined to meet the requirements of public health surveillance covered by the U.S. Department of Health and Human Services Policy for the Protection of Human Research Subjects as defined in 45 CFR 46.102, and the decision was made that this project was nonresearch and did not require ethical review by the CDC Human Research Protection Office. Ethical approval was waived and informed consent was not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are provided.COVID-19coronavirus disease 2019SARS-CoV-2severe acute respiratory syndrome coronavirus 2RT-PCRreal-time reverse transcription polymerase chain reaction